Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 5,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Subjects Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

NCT01619839
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
NKTR-181, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Mobile, Alabama • Tucson, Arizona • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2Phase 3 Interventional

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

NCT00097357
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin, Warfarin, Enoxaparin Placebo, Apixaban Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

NCT05436912
View directory record Official record
Conditions
Healthy, Hepatic Impairment
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
7
States / cities
Anaheim, California • Monterey Park, California • Tustin, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

NCT03448081
View directory record Official record
Conditions
Pruritus, Psoriasis
Interventions
SNA-120, Placebo, Calcipotriene
Drug
Lead sponsor
Sienna Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Anniston, Alabama • Mobile, Alabama • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Study of Secukinumab With 2 mL Pre-filled Syringes

NCT02748863
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Secukinumab 2 mL form, Secukinumab 1 mL form
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

NCT02070939
View directory record Official record
Conditions
Healthy
Interventions
PF-06260414, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

NCT00906399
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
BIIB017 (peginterferon beta-1a), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Phoenix, Arizona • Ponte Vedra Beach, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

NCT02109172
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
TD-4208, Placebo
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

NCT03345836
View directory record Official record
Conditions
Crohn's Disease
Interventions
Matching Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 20, 2026, 1:43 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

NCT06545500
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg), Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

NCT05518734
View directory record Official record
Conditions
Pain
Interventions
VX-708, Itraconazole, Midazolam, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects

NCT01633944
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Mobile, Alabama • Phoenix, Arizona • Anaheim, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

NCT03717272
View directory record Official record
Conditions
Marijuana Abuse
Interventions
AEF0117, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
21 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 20, 2026, 1:43 PM EDT
Not listed Phase 4 Interventional

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

NCT05109312
View directory record Official record
Conditions
Analgesia
Interventions
Bupivacaine Hydrochloride, HTX-011, Luer lock applicator, Ibuprofen, Acetaminophen
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Little Rock, Arkansas • Sarasota, Florida • Tulsa, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion

NCT02247765
View directory record Official record
Conditions
Healthy, Hypoxia
Interventions
Arterial line, Motion
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Results available

Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS

NCT00519636
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FPNS, FFNS, placebo FFNS, placebo FPNS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)

NCT02407353
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06648671, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 20, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCT04566445
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
GT005
Drug
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

NCT02585895
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Biological · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 20, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

NCT00058981
View directory record Official record
Conditions
Diabetes, Autoimmune
Interventions
DiaPep277
Drug
Lead sponsor
DeveloGen Israel, Ltd.
Industry
Eligibility
30 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee

NCT01919164
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Sprifermin, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Lakewood, Colorado • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

NCT01904409
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet, Rifaximin SSD 80 mg SER tablet, Rifaximin SSD 80mgIR/80mgSER tablet
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
113
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 20, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

NCT00948909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, ABT-126, donepezil
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 20, 2026, 1:43 PM EDT